GSK forms cancer immunotherapy pact with MD Anderson

04/10/2014 | Genetic Engineering & Biotechnology News

GlaxoSmithKline and the University of Texas MD Anderson Cancer Center, through its Moon Shots Program, have entered into a research-and-development collaboration centered on cancer immunotherapies. The partners agreed to look for new therapeutic approaches, assess patient responses in clinical trials and develop immunotherapy drugs using insights gained from the partnership. "This collaboration brings together MD Anderson's basic science capabilities with GSK's drug discovery and development expertise, and our growing immuno-oncology portfolio," said Axel Hoos, GSK's vice president for oncology R&D.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC